Innovation Pharmaceuticals Inc (IPIX)

[bradfordbros]

Read the following:

“This is great news that the tenth cohort has been completed, once again demonstrating the safety of Kevetrin. Our team is excited by the fact that no dose limiting toxicity (DLT) has been seen even at these higher levels, as DLT has historically been a significant hurdle for any biotech targeting p53. As such, we’re going to continue to push our novel drug as far as possible for maximum therapeutic effect and to collect the most robust data set possible,” commented Dr. James Alexander, Chief Operating Officer at Cellceutix. “We have seen some encouraging data in different types of cancer to date and the eleventh cohort gives us the opportunity to add to our knowledge base in preparation for future clinical studies.” - See more at: http://cellceutix.com/tenth-cohort-completed-in-cellceutix-clinical-trial-of-anti-cancer-drug-kevetrin-no-adverse-events-reported/#sthash.ZCVrrzfv.dpuf